T611
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- T611
- DrugBank Accession Number
- DB06391
- Background
T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 462.48
Monoisotopic: 462.132153626 - Chemical Formula
- C19H22N6O6S
- Synonyms
- 2-(3S-3-METHYLMORPHOLINO)-4-(IMIDAZOL-1-YL)-6-METHYL-5-NITROPYRIMIDINE BENZENESULFONATE
- BENZENESULFONIC ACID; (3S)-4-(4-IMIDAZOL-1-YL-6-METHYL-5-NITRO-PYRIMIDIN-2-YL)-3-METHYL-MORPHOLINE
- MORPHOLINE, 4-(4-(1H-IMIDAZOL-1-YL)-6-METHYL-5-NITRO-2-PYRIMIDINYL)-3-METHYL-, (3S)-, BENZENESULFONATE (1:1)
- External IDs
- AIDS-111759
- T-2611
- T-611
Pharmacology
- Indication
Investigated for use/treatment in viral infection and cytomegalovirus (CMV) retinitis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
T611 is an oral anti-cytomegalovirus (CMV) drug candidate. T611 inhibits a CMV enzyme that is essential for viral replication. The new study will explore the efficacy of T611 in HIV/AIDS patients with CMV infection. CMV is a ubiquitous herpes virus that causes serious disease in immuno-compromised patients.
Target Actions Organism UTransmembrane anterior posterior transformation protein 1 homolog Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YJN0IQX3S4
- CAS number
- 350595-61-8
- InChI Key
- GPJYNQNPOAOBPJ-FVGYRXGTSA-N
- InChI
- InChI=1S/C13H16N6O3.C6H6O3S/c1-9-7-22-6-5-18(9)13-15-10(2)11(19(20)21)12(16-13)17-4-3-14-8-17;7-10(8,9)6-4-2-1-3-5-6/h3-4,8-9H,5-7H2,1-2H3;1-5H,(H,7,8,9)/t9-;/m0./s1
- IUPAC Name
- SMILES
- OS(=O)(=O)C1=CC=CC=C1.[H][C@]1(C)COCCN1C1=NC(C)=C(C(=N1)N1C=CN=C1)N(=O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 8066201
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Plays a role in primary cilia formation (PubMed:26365339). May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similarity). May be involved in cartilage and bone development (By similarity). May play a role in the differentiation of cranial neural crest cells (By similarity)
- Specific Function
- Growth hormone-releasing hormone receptor activity
- Gene Name
- TAPT1
- Uniprot ID
- Q6NXT6
- Uniprot Name
- Transmembrane anterior posterior transformation protein 1 homolog
- Molecular Weight
- 64258.96 Da
Drug created at March 19, 2008 16:28 / Updated at August 08, 2024 23:11